1Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinema patients with at least one osteolytic lesion [J]. Cancer, 2004,100( 1 ) :36-43.
2Croucher P, Jagdev S, Coleman R. The anti-tumor potential of zoledronic acid [J]. Breast, 2003,12(2) :30-36.
4Cordon DH. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase Ⅲ trials [J]. Clin Breast Cancer, 2005, 6(2) :125-131.
二级参考文献13
1Evdokiou A,Labrinidis A.Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis[J].Bone,2003,33(2):216.
2Neville-Webbe H,Coleman R E.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med,2003,17(6):539.
3Witters L M,Crispino J.Effect of the Combination of Docetaxel,Zoledronic Acid,and a COX-2 Inhibitor on the Growth of Human Breast Cancer Cell Lines[J].Am J Clin Oncol,2003,26(4):S92.
4Jagdev S P,Croucher P I,Coleman R E.Zoledronate induces apoptosis of breast cancer cells in vitro-Evidence for additive and synergistic effects with taxol and tamoxifen[J].Proc Am Soc Clin Oncol,2000,19:664a.
5Tassone P,Forciniti S,Galea E,et al.Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines[J].Leukemia,2000,14:841.
6Chen T,Berenson J.Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases[J].J Clin Pharmacol,2002,42(11):1228.
7Skerjanec A,Berenson J.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2):154.
8Lipton A,Zheng M,Seaman J,et al.Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma[J].Cancer,2003,98(5):962.
9Smith M R,Eastham J,Gleason D M.Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer[J].J Urol,2003,169(6):2008.
10Rosen L S,Gordon D,Tchekmedyian S,et al.Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors[J].J Clin Oncol,2003,21(16):3150.
5Coxon JP, Oades GM ,Kirby RS ,et al.Zoledronic acid induces apopto-sis and inhibits adhesion to mineralized matrix in prostate cancer cellsvia inhibition of protein prenylation[J].BJU lat, 2004,94 ( 1 ) : 164.
